Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant SARS-CoV-2 Spike S1 antibody (RBD)

Reactivity: SARS Coronavirus-2 (SARS-CoV-2) ELISA, Neut Host: Human Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN6952616
  • Target See all SARS-CoV-2 Spike S1 Antibodies
    SARS-CoV-2 Spike S1
    Antibody Type
    Recombinant Antibody
    Biological Activity
    Active
    Binding Specificity
    • 12
    • 3
    • 2
    • 2
    • 1
    RBD
    Reactivity
    • 40
    • 7
    • 4
    • 3
    • 3
    • 3
    • 2
    • 2
    • 1
    • 1
    SARS Coronavirus-2 (SARS-CoV-2)
    Host
    • 15
    • 10
    • 5
    • 3
    • 2
    • 2
    • 2
    • 1
    • 1
    Human
    Expression System
    HEK-293 Cells
    Clonality
    • 27
    • 9
    • 5
    Monoclonal
    Conjugate
    • 35
    • 3
    • 1
    • 1
    • 1
    This SARS-CoV-2 Spike S1 antibody is un-conjugated
    Application
    • 40
    • 9
    • 8
    • 7
    • 5
    • 5
    • 4
    • 4
    • 3
    • 3
    • 2
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    • 1
    ELISA, Neutralization (Neut)
    Purpose
    Anti-SARS-CoV-2 neutralizing antibody (Human IgG1)
    Specificity
    The product is specific for SARS-CoV-2 Spike Protein S1 subunit and its RBD domain, and can inhibit the interaction between SARS-CoV-2 Spike Protein RBD and ACE2.
    Cross-Reactivity (Details)
    This product is a specific neutralizing antibody against SARS-CoV-2 Spike Protein RBD domain and no cross-reactivity was detected against SARS-CoV Spike protein. The cross-reactivity with other coronaviruses has not been tested yet.
    Characteristics
    Anti-SARS-CoV-2 Neutralizing Antibody, Human IgG1 recognizes the SARS-CoV-2 Spike Protein RBD domain and can inhibit the interaction between SARS-CoV-2 Spike Protein RBD and ACE2. It has not been tested with other coronovirus. It is expressed from human 293 cells (HEK293).
    Purity
    > 95 % as determined by SDS-PAGE.
    Sterility
    0.22 μm filtered
    Isotype
    IgG1
    Biological Activity Comment
    IC50 = 1.47 μg/mL using SARS-CoV-2 Inhibitor screening Kit
    Top Product
    Discover our top product SARS-CoV-2 Spike S1 Primary Antibody
  • Application Notes
    Optimal working dilution should be determined by the investigator.
    Restrictions
    For Research Use only
  • Format
    Lyophilized
    Buffer
    Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4 . Normally trehalose is added as protectant before lyophilization.
    Storage
    4 °C,-20 °C,-80 °C
    Storage Comment
    For long term storage, the product should be stored at lyophilized state at -20°C or lower.
    This product is stable after storage at:
    4-8°C for 12 months in lyophilized state,
    -70°C for 3 years under sterile conditions after reconstitution.
  • Wu, Wu, Wang, Liu, Chu, Jiang, Kwong, Chow, Li, Chen: "Microfluidic particle dam for direct visualization of SARS-CoV-2 antibody levels in COVID-19 vaccinees." in: Science advances, Vol. 8, Issue 22, pp. eabn6064, (2022) (PubMed).

    Chouchane, Grivel, Farag, Pavlovski, Maacha, Sathappan, Al-Romaihi, Abuaqel, Ata, Ismail Chouchane, Remadi, Halabi, Rafii, Al-Thani, Marr, Subramanian, Shan: "Dromedary camels as a natural source of neutralizing nanobodies against SARS-CoV-2." in: JCI insight, (2021) (PubMed).

    Munitz, Edry-Botzer, Itan, Tur-Kaspa, Dicker, Marcoviciu, Goren, Mor, Lev, Gottesman, Muhsen, Cohen, Stein, Qimron, Freund, Wine, Gerlic: "Rapid seroconversion and persistent functional IgG antibodies in severe COVID-19 patients correlates with an IL-12p70 and IL-33 signature." in: Scientific reports, Vol. 11, Issue 1, pp. 3461, (2021) (PubMed).

    Apostolou, Kyritsi, Vontas, Loizou, Hadjilouka, Speletas, Mouchtouri, Hadjichristodoulou: "Development and performance characteristics evaluation of a new Bioelectric Recognition Assay (BERA) method for rapid Sars-CoV-2 detection in clinical samples." in: Journal of virological methods, Vol. 293, pp. 114166, (2021) (PubMed).

    Leach, Miller, Bentley, Mattiuzzo, Thomas, McAndrew, Van Montfort, Rabbitts: "Implementing a method for engineering multivalency to substantially enhance binding of clinical trial anti-SARS-CoV-2 antibodies to wildtype spike and variants of concern proteins." in: Scientific reports, Vol. 11, Issue 1, pp. 10475, (2021) (PubMed).

    Park, Bazzill, Son, Nam, Shin, Ochyl, Stuckey, Meagher, Chang, Song, Montefiori, LaBranche, Smith, Xu, Moon: "Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2." in: Journal of controlled release : official journal of the Controlled Release Society, Vol. 330, pp. 529-539, (2020) (PubMed).

    Xiong, Qu, Ciazynska, Hosmillo, Carter, Ebrahimi, Ke, Scheres, Bergamaschi, Grice, Zhang, Nathan, Baker, James, Baxendale, Goodfellow, Doffinger, Briggs: "A thermostable, closed SARS-CoV-2 spike protein trimer." in: Nature structural & molecular biology, Vol. 27, Issue 10, pp. 934-941, (2020) (PubMed).

  • Target
    SARS-CoV-2 Spike S1
    Abstract
    SARS-CoV-2 Spike S1 Products
    Synonyms
    E2 antibody, Surface Glycoprotein antibody, S antibody
    Target Type
    Viral Protein
    Background
    Protein S (PROS1) is glycoprotein and expressed in many cell types supporting its reported involvement in multiple biological processes that include coagulation, apoptosis, cancer development and progression, and the innate immune response. Known receptors bind S1 are ACE2, DPP4, CEACAM etc.. It's been reported that 2019-nCoV can infect the human respiratory epithelial cells through interaction with the human ACE2 receptor. The spike protein is a large type I transmembrane protein containing two subunits, S1 and S2. S1 mainly contains a receptor binding domain (RBD), which is responsible for recognizing the cell surface receptor. S2 contains basic elements needed for the membrane fusion.The S protein plays key parts in the induction of neutralizing-antibody and T-cell responses, as well as protective immunity.
    Gene ID
    43740568
    UniProt
    P0DTC2
You are here:
Support